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Vigabatrin in the management of generalized 
seizures in children 
RICHARD E. APPLETON 
The Roald Dahl EEG Unit, Royal Liverpool Children's Hospital (Alder Hey), Liverpool L 12 2AP, UK 
The interpretation of the results of the use of vigabatrin (VGB) in generalized seizures and epilepsies in 
children has been difficult. Most studies have assessed patients on the basis of both seizure type and epilepsy 
syndrome and the numbers of patients have been small. Some 'generalized' epilepsy syndromes { pecifically the 
Lennox-Gastaut syndromel are characterized by multiple seizure types which are frequently not analysed 
individually in terms of drug response. By contrast West syndrome iseasier to evaluate as the spasms are the 
only, and characteristic, seizure type. Vigabatrin has been used as both add-on, and mohotherapy in the 
treatment ofspasms. The results of add-on studies uggest that symptomatic spasms respond best, with 40- 
100% of chilren becoming spasm-free and many others showing a reduction in seizures of over 50%. The 
limited, reported ata on VGB-monotherapy in West syndrome have been encouraging with over 50% of 
patients experiencing a total and sustained control of seizures with minimal or no adverse vents; however, the 
pattern of response (symptomatic cases responding better than cryptogenic casesl, has not, as yet, been 
confirmed. The 'non-progresive' myoclonic epilepsies tend to be exacerbated with 25-50% of patients experi- 
encing an increase in seizure frequency; this is an interesting observation i view of the improvement seen in 
infantile spasms, which are also classified as a myoclonic seizure. The use of VGB in other generalized seizures 
and epilepsy syndromes has been neither assessed, nor reported. This reflects the fact that these seizures/ 
syndromes are easily and well controlled using the 'older' anti-epileptic drugs. 
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INTRODUCTION 
The introduction (and licensing) of vigabatrin 
in 1989 was for the treatment of epilepsy which 
was not satisfactorily controlled by other 
anti-epileptic drugs; to date, its predominant 
prescription has been in refractory partial 
(cryptogenic/symptomatic localization-related' 
seizures and epilepsies, in which it has 
achieved considerable success 2"3. Its use has 
subsequently been extended to generalized 
symptomatic/crypt0genic seizures (and epi- 
lepsy syndromes) in which both the reporting 
of results, and success, has been more limited. 
The purpose of this paper is to review the effi- 
cacy of vigabatrin in generalized seizures and 
epilepsies principally in the West and Lennox- 
Gastaut syndromes. 
WEST SYNDROME 
Until recently the treatment of spasms in West 
syndrome relied upon anecdotal and retrospec- 
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tive studies, using drugs which have an 
unknown mechanism and serious side effects. 
Vigabatrin is the first of the 'newer' anti- 
epileptic drugs to be used in this syndrome, 
initially as 'add-on '4, and subsequently as 
monotherapy 5.6. 
In a single, uncontrolled study VGB was ef- 
fective in controlling previously drug-resistant 
spasms; this open, add-on study involved 70 
children, aged between 2 months and 13 years 
in whom the onset of spasms was under the age 
of 1 year 4. The spasms were classified as symp- 
tomatic (33 patients) and cryptogenic (37 
patients); aetiologies in the symptomatic cases 
included tuberous clerosis (14), other cerebral 
malformations (9) and ischaemia (6). The 
dosage of VGB was 50-150 mg/kg/day in chil- 
dren and 100-200mg/kg/day in infants; 66 
children were receiving other anti-epileptic 
drugs at the time VGB was introduced. The 
patients were assessed at 5 months (evaluation 
phase) and subsequently for up to 33 months 
(long-term phase). Thirty-seven of the 68 
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patients (54%) who were evaluated at 5 months 
showed resolution of spasms; efficacy was par- 
ticularly striking in patients with symptoma- 
tic spasms due to tuberous clerosis with 10 of 
14 (71%) showing a complete suppression (Fig. 
1). In the long-term phase, in which 55 patients 
were evaluated, 30 (55%) continued to show a 
complete resolution of spasms including all the 
patients with tuberous clerosis (Fig. 1). In the 
patients who experienced complete control of 
their spasms, eight were ultimately controlled 
on VGB-monotherapy. An additional 10% of 
patients howed a 50% or greater reduction in 
spasms. The data showed clearly that patients 
with symptomatic spasms responded better 
than those with cryptogenic spasms, which is 
contrary to current textbook teaching. Adverse 
events were common, occurring in 26% of 
patients; sedation, hypotonia and agitation 
were the most frequently encountered, and two 
patients required early withdrawal of VGB, 
due to hypertonia and hypotonia, respectively. 
Finally, tolerance (leading to discontinuation 
of the drug) developed in 10 of the 55 patients 
(18%). 
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Fig. 1. Efficacy of vigabatrin according to aetiology in 
children with West syndrome. 
In view of this preliminary data, suggesting 
that VGB may be an effective and safe drug in 
the treatment of spasms, attention has, not 
surprisingly, focused on using it as the initial 
preferred drug  5'6, instead of ACTH and cortico- 
steroids. 
At the Royal Liverpool Children's Hospital, 
Alder Hey, VGB has been used as initial 
monotherapy in the treatment of infantile 
spasms for the past 2 years: the first 15 chil- 
dren have already been reported 5. To date 20 
children, aged 3-11 months, have been 
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treated, 14 with symptomatic, four with cryp- 
togenic and two with idiopathic (normal devel- 
opment and neurological findings), spasms. 
Aetiologies in the symptomatic cases included 
cerebral dysgenesis ( even patients), neonatal 
hypoxic ischaemic encephalopathy (2), peri- 
natal periventricular haemorrhage (2), tuber- 
ous sclerosis (2) and unilateral cerebral 
astrocytoma (1). Vigabatrin was started at di- 
agnosis at 50-80 mg/kg/day increasing over 3 
days to a maximum of 100-150 mg/kg daily. 
Overall, 16 of the 20 patients (80%) showed 
75% or greater reduction in spasms; 13 of these 
16 patients (65% of the entire group) showed a
complete suppression of spasms which has 
been sustained for up to 30 months. The results 
are summarized in Table 1. Only four of the 20 
patients demonstrated no response to VGB; 
alternative treatments in these patients 
(including ACTH, sodium valproate and nitra- 
zepam) have not completely suppressed the 
spasms. The most striking observation was 
that all those children who responded id so 
within 72 hours of starting treatment, includ- 
ing total suppression. 
Table 1 : Summary of results in the 20 patients 
Number Efficacy Relapse Follow-up period 
(months) 
7 100% - -  8-30 
6 100% 1(5)* 4-9 
3 75-90% 1 2-8 
4 0 - -  6-18 
* Only one patient in this group showed a relapse of 
spasms (after 4 months); the remaining five patients have 
developed other, predominantly partial and myoclonic 
seizures. 
Hypsarrhythmia disappeared in all seven 
patients who showed a sustained resolution of 
the spasms including the two children with 
idiopathic, three of the four children with cryp- 
togenic, and two of the 14 children with symp- 
tomatic spasms (due to tuberous clerosis and 
cerebral dysgenesis, respectively). In those 
patients who suffered a relapse of spasms after 
initial control there was no clear pattern of 
response in terms of the EEG; in some patients 
the hypsarrhythmia persisted uring control 
and relapse, while in others the EEG remained 
abnormal but not obviously hypsarrhythmic. 
There were no aetiological, clinical or elec- 
troencephalographic features (data not shown) 
which distinguished responders from non- 
responders, but this probably reflects the small 
number of patients in the study; the two chil- 
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dren with 'idiopathic' spasms have shown a 
complete, and sustained control, with no other 
seizure types and normal development, as have 
three of the four children with cryptogenic 
spasms. 
There did not appear to be an obvious dose- 
response relationship, although this was not 
formally assessed; it was our impression that 
most of the responders howed a dramatic re- 
duction in spasms at the lower, introductory 
dose of 50-80 mg/kg/day. No dose response has 
been demonstrated in a formal, dose-ranging 
study undertaken in older children 7. 
No adverse side-effects were seen in the 20 
patients. 
A more recent report from the Netherlands 6 
describes ix children aged between 3 and 6 
months, treated with VGB monotherapy. 
Three had symptomatic, and three cryptogenic 
spasms. The dose of VGB was 50mg/kg/day 
initially increasing, if necessary, to 100 mg/kg/ 
day. All six children showed a 50% or greater 
reduction in spasms. In two the response was 
complete (100%) and sustained for up to 24 
months; in two others there was a relapse after 
initial complete control (relapse of spasms in 
one, development of other seizure types in the 
other) and the remaining two showed a re- 
duction of 50% and 90% of spasms (both 
demonstrated improved control at the higher 
dose). There was no comment on the rate of 
response, i.e. how rapidly spasms ceased after 
the drug was started. Adverse events occurred 
in two children (hypotonia, hyperactivity). 
The only other published report (abstract 
form only), describes five patients who were 
reported to show a 50-75% reduction in 
spasms after 6 months of treatment--no 
further details were available s.
These preliminary data suggest that viga- 
batrin could be considered as the preferred, 
initial treatment for infantile spasms. The re- 
sponse rate indicates that if spasms have not 
been controlled after 5 or 6 days of treatment 
with VGB, alternative anti-epileptic drugs can 
then be introduced without affecting the short- 
term or long-term outcome, with respect to 
control of spasms, the development of'late' epi- 
lepsy or intellectual function. However, there 
are still some outstanding questions regarding 
the use of VGB, particularly the long-term 
effects of the drug, and how long after control 
of the spasms the drug can be withdrawn; with 
regard to this latter question we have recently 
and successfully withdrawn VGB after 12, 16 
and 24 months of complete seizure control in 
three children. It is likely that the drug could 
be discontinued after a shorter period of treat- 
ment, but this needs further evaluation and 
confirmation. 
LENNOX-GASTAUT SYNDROME 
The Lennox-Gastaut syndrome is considered 
by many to be an extension of West syndrome 
and is characterized by multiple seizure types; 
unfortunately the syndrome or label is fre- 
quently over-diagnosed and is often used 
inappropriately for any patient with difficult 
epilepsy. As a result, evaluation of patients 
with the syndrome has been difficult. 
Published data reporting the use of VGB in 
children with Lennox-Gastaut syndrome are 
limited and the results are inconsistent. An 
open add-on study (published in abstract form 
only) 9 of 20 patients, reported that 60% of 
patients experienced a 60-100% reduction in 
seizures, although it was unclear whether just 
one, or all, seizure types were reduced. In other 
studies 2'1°, a seizure reduction of between 30 
and 50% in Lennox-Gastaut syndrome has 
been reported in 40-50% of patients but the 
numbers involved have been very small (often 
less than 10), and again, analysis has not 
usually been performed on specific seizure 
types. In our series of 43 patients, six of whom 
had the Lennox-Gastaut syndrome, none of 
them achieved a greater than 25% reduction in 
total seizure frequency 3.
NON-PROGRESSIVE MYOCLONIC SEIZURES 
Most studies have demonstrated that myo- 
clonic seizures, occurring either in isolation, or 
in one of the non-progressive myoclonic epi- 
lepsies, tend to be exacerbated 2'3 occasionally 
necessitating withdrawal of VGB. In our ex- 
perience this has occasionally been ac- 
companied by an increase in spike or polyspike 
activity in the EEG in a number of patients. 
This is an interesting observation in view of 
the beneficial effect of VGB on infantile 
spasms, which are also classified as a myo- 
clonic seizure; these observations are not 
necessarily contradictory and may be 
explained by the heterogenous pathophysi- 
ology of infantile spasms. Thus, for instance, 
symptomatic ases with focal pathology (e.g. 
unilateral dysgenesis or tumour) may cause 
partial seizures with rapid secondary general- 
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ization, manifest as clusters of spasms; this has 
been confirmed by simultaneous split-screen 
video-EEG recording, in both our, and others' 
experience. (This may have implications for 
any future classifications ofepilepsies and epi- 
lepsy syndromes.) That partial, secondarily 
generalized seizures (in this case spasms) 
should respond well to VGB is not surprising 
given the proven efficacy of the drug in partial 
(particularly symptomatic) seizures 2"3' ~o. 
OTHER GENERALIZED EPILEPSIES-- 
IDIOPATHIC 
The use of VGB in the idiopathic generalized 
epilepsies (group 2.1 in the 1989 ILAE Classifi- 
cation l) has either not been evaluated or has 
not been reported. This is not unexpected as 
the majority of these epilepsies (and seizures) 
tend to be relatively well-controlled with the 
'older' anti-epileptic drugs, and have a gener- 
ally benign outcome. The numbers of patients 
experiencing 'primary' generalized tonic- 
clonic, tonic or absence seizures and treated 
with VGB have been small and less than 30c~ 
of patients have experienced at least a 50c~ 
reduction in seizures 2'3. Finally, our own 
observations would suggest that the early 
morning myoclonic seizures seen in juvenile 
myoclonic epilepsy may occur more frequently 
in patients treated with this drug. 
CONCLUSION 
Vigabatrin has been used infrequently, and 
with limited success in the generalized epilep- 
sies and epilepsy syndromes of childhood. The 
one 'generalized' epilepsy syndrome where the 
drug appears to be both effective and safe, and 
offer a clear advantage compared to the older, 
more established treatments, is West syn- 
drome, particularly if of symptomatic origin. 
Information on both the duration of treatment 
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with VGB in this syndrome, and on the long- 
term effects of the drug is still required; in the 
interim VGB should arguably become the pre- 
ferred, initial drug for the treatment of infan- 
tile spasms and West syndrome. 
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